This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants Experiencing Adverse Events
Timeframe: Up to approximately 33 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of Ubrogepant
Timeframe: Up to approximately 3 days
AUC From Time 0 to the Time Infinity (AUCinf) of Ubrogepant
Timeframe: Up to approximately 3 days
Maximum Observed Plasma Concentration (Cmax) of Ubrogepant
Timeframe: Up to approximately 3 days
Time lag between dosing and drug to appear in systemic circulation following extravascular administration (Tlag) of Ubrogepant
Timeframe: Up to approximately 3 days
Time to maximum observed plasma concentration (Tmax) of Ubrogepant
Timeframe: Up to approximately 3 days
Apparent terminal phase elimination constant (λz) of Ubrogepant
Timeframe: Up to approximately 3 days
Terminal phase elimination half-life (t1/2) of Ubrogepant
Timeframe: Up to approximately 3 days
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Ubrogepant
Timeframe: Up to approximately 3 days
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Ubrogepant
Timeframe: Up to approximately 3 days